Becton Dickinson Clocks Strong Q2 Sales From Medical Devices, Raises Annual Outlook
Portfolio Pulse from Vandana Singh
Becton, Dickinson, and Company (BDX) reported Q3 adjusted EPS of $2.96, beating the consensus of $2.89. Sales were $4.88 billion, up 5.1% Y/Y, slightly beating the consensus of $4.83 billion. The company's medical segment reported 11.1% growth, and its interventional business grew by 6.7%. However, life sciences revenue dropped by 6.3%. The FDA recently approved BD Alaris Infusion System. The company expects 2023 revenues of approximately $19.3 billion.
August 04, 2023 | 1:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Becton, Dickinson, and Company reported strong Q3 results, beating EPS and sales consensus. The company's medical and interventional businesses showed growth, while life sciences revenue dropped. The FDA approval of BD Alaris Infusion System is a positive development.
Becton, Dickinson, and Company reported strong Q3 results, with both EPS and sales beating consensus. This indicates a strong financial performance, which is likely to be positively received by investors. The growth in the company's medical and interventional businesses is a positive sign, indicating strong demand for these segments. However, the drop in life sciences revenue is a concern and could potentially impact future earnings. The FDA approval of BD Alaris Infusion System is a positive development, as it allows the company to return to full commercial operations for this product. This could potentially boost future revenues. Therefore, the overall impact on the company's stock is likely to be positive in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100